Diagnosis and treatment of ovarian cancer

B Orr, RP Edwards - Hematology/Oncology Clinics, 2018 - hemonc.theclinics.com
The diagnosis and treatment planning for newly diagnosed ovarian adenocarcinomas are
unique among solid cancers. Ovarian cancer is insidious in presentation with few sentinel …

[HTML][HTML] Peritoneal carcinomatosis

F Coccolini, F Gheza, M Lotti, S Virzì… - World journal of …, 2013 - ncbi.nlm.nih.gov
Several gastrointestinal and gynecological malignancies have the potential to disseminate
and grow in the peritoneal cavity. The occurrence of peritoneal carcinomatosis (PC) has …

NCCN guidelines insights: Ovarian cancer, version 1.2019: Featured updates to the NCCN guidelines

DK Armstrong, RD Alvarez, JN Bakkum-Gamez… - Journal of the National …, 2019 - jnccn.org
Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the
United States, with less than half of patients living> 5 years from diagnosis. A major …

[HTML][HTML] The 30-year experience—A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the …

J Desiderio, J Chao, L Melstrom, S Warner… - European Journal of …, 2017 - Elsevier
Importance Hyperthermic intraperitoneal chemotherapy (HIPEC) has been used within
various multimodality strategies for the prevention and treatment of gastric cancer peritoneal …

Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer

K Jaaback, N Johnson… - Cochrane database of …, 2016 - cochranelibrary.com
Background Ovarian cancer tends to be chemosensitive and confine itself to the surface of
the peritoneal cavity for much of its natural history. These features have made it an obvious …

[HTML][HTML] Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy

MD Goodman, S McPartland, D Detelich… - Journal of …, 2016 - ncbi.nlm.nih.gov
Peritoneal spread of tumors is a major problem in cancer management. Patients develop a
marked deterioration in quality of life and shortened survival. This is in part due to bowel …

Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining 'optimal'residual disease

SJ Chang, RE Bristow - Gynecologic oncology, 2012 - Elsevier
Over the past 40years, the survival of patients with advanced ovarian cancer has greatly
improved due to the introduction of combination chemotherapy with platinum and paclitaxel …

Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal …

M Robella, M Vaira, M De Simone - World journal of surgical oncology, 2016 - Springer
Background Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a new treatment
that applies chemotherapeutic drugs into the peritoneal cavity as an aerosol under pressure …

A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer

LM Chiva, A Gonzalez-Martin - Gynecologic Oncology, 2015 - Elsevier
Objective Our objective was to review the published experiences of the use of hyperthermic
intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian …

Diagnosis and management of peritoneal metastases from ovarian cancer

E Halkia, J Spiliotis… - … research and practice, 2012 - Wiley Online Library
The management and the outcome of peritoneal metastases or recurrence from epithelial
ovarian cancer are presented. The biology and the diagnostic tools of EOC peritoneal …